![](https://investorshub.advfn.com/uicon/131536.png?cb=1704806637)
Friday, December 09, 2022 10:46:19 AM
BENZINGA 9:04 AM ET Dec-09-2022
Ambrx Biopharma Inc (NASDAQ:AMAM) announced preliminary safety and efficacy data from its Phase 2 ACE-Breast-03 study.
The data presented demonstrated a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) after treatment with ARX788 in HER2-positive mBC patients who are resistant or refractory to T-DM1.
ACE-Breast-03 is a Phase 2 study of ARX788 for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens.
Related: Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason.
Patients had a median time on therapy of 7.2 months, and treatment remains ongoing.
None of the patients experienced drug-related serious adverse events (SAEs), and all adverse events (AEs) were well tolerated, with no treatment discontinuations from AEs.
Two Phase 3 studies and one registration-enabled Phase 2 study with ARX788 conducted by Amrbrx's partner, NovoCodex Biopharmaceuticals, are ongoing in China, with projected readouts in 2023.
Price Action: AMAM shares are up 180.6% at $1.15 during the premarket session on the last check Friday.
0
Recent AMAM News
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/12/2023 08:20:50 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/12/2023 08:15:28 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/12/2023 08:10:58 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/12/2023 08:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:04:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 08:49:04 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 10/10/2023 03:35:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:07:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/25/2023 09:24:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/07/2023 08:05:50 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM